UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Improving outcomes in germ cell cancers using miRNA

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.17588359211027826-17588359211027826

2021

Volltextzugriff (PDF)

Novel radionuclide therapy combinations in prostate cancer

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231187202-17588359231187202

2023

Volltextzugriff (PDF)

A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours

Frontiers in oncology, 2022-08, Vol.12, p.931509-931509

2022

Volltextzugriff (PDF)

Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up

Cancer imaging, 2022-10, Vol.22 (1), p.58-8, Article 58

2022

Volltextzugriff (PDF)

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359221092486-17588359221092486

2022

Volltextzugriff (PDF)

Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study

JMIR cancer, 2022-10, Vol.8 (4), p.e39725-e39725

2022

Volltextzugriff (PDF)

Case of the month from the Department of Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Australia: recurrent metastatic spermatocytic tumour successfully treated with salvage systemic chemotherapy

BJU international, 2024-05

2024

Volltextzugriff (PDF)

Active surveillance: minimising treatment while maximising outcomes in testis cancer

Translational andrology and urology, 2023-09, Vol.12 (9), p.1371-1374

2023

Volltextzugriff (PDF)

Implementing ‘Goals of Care’ discussion and palliative care referral for patients with advanced lung cancer: an outpatient‐based pilot project

Internal medicine journal, 2021-04, Vol.51 (4), p.540-547

2021

Volltextzugriff (PDF)

Clinical utility of FDG PET-CT in stage 1 and advanced testicular seminoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5027-5027

2021

Volltextzugriff (PDF)

Trial in progress: PREPARE—Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer (TC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS432-TPS432

2023

Volltextzugriff (PDF)

Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence

Cancer prevention research (Philadelphia, Pa.), 2021-11, Vol.14 (11), p.983-994

2021

Volltextzugriff (PDF)

Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer

BJU international, 2024-07

2024

Volltextzugriff (PDF)

Treatment de-escalation for stage II seminoma

Nature reviews. Urology, 2023-08, Vol.20 (8), p.502

2023

Volltextzugriff (PDF)

Trial in progress: PRESTIGE—Primary retroperitoneal lymph node dissection (RPLND) for clinical stage II (CSII) testicular germ cell tumour (TGCT) and its impact on health-related quality of life (HRQoL) compared to chemotherapy or radiotherapy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS433-TPS433

2023

Volltextzugriff (PDF)

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.483-483

2022

Volltextzugriff (PDF)

CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5100-TPS5100

2023

Volltextzugriff (PDF)

GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5099-TPS5099

2023

Volltextzugriff (PDF)

A case of de novo diagnosis anti‐neutrophil cytoplasmic antibody‐negative pauci‐immune necrotising glomerulonephritis in pregnancy

Internal medicine journal, 2017-05, Vol.47 (5), p.600-601

2017

Volltextzugriff (PDF)

Efficacy of systemic therapy following [ 177 Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.77-77

2023

Volltextzugriff (PDF)

Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC

Journal of thoracic oncology, 2016-11, Vol.11 (11), p.e131-e133

2016

Volltextzugriff (PDF)

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma

BJU international, 2024-02, Vol.133 (S3), p.57-67

2024

Volltextzugriff (PDF)

Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed

JAMA oncology, 2021-09, Vol.7 (9), p.1401

2021

Volltextzugriff (PDF)

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4537-4537

2022

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(30)
Berichte
(4)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Improving outcomes in germ cell cancers using miRNA

Novel radionuclide therapy combinations in prostate cancer

A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours

Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study

Case of the month from the Department of Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Australia: recurrent metastatic spermatocytic tumour successfully treated with salvage systemic chemotherapy

Active surveillance: minimising treatment while maximising outcomes in testis cancer

Implementing ‘Goals of Care’ discussion and palliative care referral for patients with advanced lung cancer: an outpatient‐based pilot project

Clinical utility of FDG PET-CT in stage 1 and advanced testicular seminoma

Trial in progress: PREPARE—Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer (TC)

Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence

Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer

Treatment de-escalation for stage II seminoma

Trial in progress: PRESTIGE—Primary retroperitoneal lymph node dissection (RPLND) for clinical stage II (CSII) testicular germ cell tumour (TGCT) and its impact on health-related quality of life (HRQoL) compared to chemotherapy or radiotherapy

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule

CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906

GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903)

A case of de novo diagnosis anti‐neutrophil cytoplasmic antibody‐negative pauci‐immune necrotising glomerulonephritis in pregnancy

Efficacy of systemic therapy following [ 177 Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC

The Dedicated Imaging Post‐Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low‐risk biochemical recurrence after radical prostatectomy

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma

Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma

Suchergebnisse filtern